research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
Search
for
Sort by
Research
450-480 / 1000+ results 
research Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report.
Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
research CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.
Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
research Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin
Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics
research Mesotherapy with dutasteride in the treatment of androgenetic alopecia
research Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research Patient-reported outcomes of adverse events after perioperative chemotherapy for breast cancer: A prospective observational study
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
research A Prospective Observational Study for Assessment of Chemotherapy-Induced Adverse Drug Reactions in Cancer Patients
Females had more chemotherapy side effects than males, with many being preventable.
research Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
Using finasteride or dutasteride does not increase the risk of male breast cancer.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Abstract SS02-02: Chemoprevention: Poised for Success
Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Unusual Anti-Angiogenic Effect of Combined Hormonal Blockade
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Tamoxifen for flutamide/finasteride-induced gynecomastia
Tamoxifen effectively treats gynecomastia without causing impotence.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Virilizing Ovarian Tumor in a Postmenopausal Women
research Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
research Tamoxifen-Induced Total Alopecia
Tamoxifen can cause total hair loss but its benefits outweigh this side effect.
research Current Aspects of Antiandrogen Therapy in Women
Antiandrogen therapy is effective and well tolerated for treating women's androgenic disorders like hirsutism, acne, and hair loss.
research Journal for ReAttach Therapy and Developmental Diversities
Ayurveda-based care improved quality of life for breast cancer patients without serious side effects.
research Gender-Affirming Hormone Therapy for Transgender Females
Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.
research Postmenopausal Hyperandrogenism in a Patient With an Adrenal Adenoma: How Should We Approach It?
Removing both ovaries treated the woman's excess male hormone symptoms.
research Controversies Regarding Transdermal Androgen Therapy in Postmenopausal Women
Testosterone therapy may slightly improve sexual function in postmenopausal women, but its long-term safety is unknown.